Marco Losa1, Pietro Mortini2, Angela Pagnano2, Mario Detomas2, Maria Francesca Cassarino3, Francesca Pecori Giraldi3,4. 1. Pituitary Unit of the Division of Neurosurgery, IRCCS San Raffaele, University Vita-Salute, Milan, MI, Italy. losa.marco@hsr.it. 2. Pituitary Unit of the Division of Neurosurgery, IRCCS San Raffaele, University Vita-Salute, Milan, MI, Italy. 3. Istituto Auxologico Italiano IRCCS, Neuroendocrine Research Laboratory, Milan, MI, Italy. 4. Department of Clinical Sciences & Community Health, University of Milan, Milan, Italy.
Abstract
PURPOSE: somatic mutations in the ubiquitin-specific protease 8 (USP8) gene have recently been described in patients with Cushing's disease (CD). The aim of the study is to verify whether USP8 mutation may predict early and late outcome of pituitary surgery in patients with CD operated at a single institution. METHODS: We performed a retrospective genetic analysis of 92 adrenocorticotropic hormone (ACTH)-secreting pituitary adenomas. Specimens were screened for USP8 hotspot mutations in the exon 14 with Sanger sequencing. Hormonal and surgical data were compared between USP8 variant carriers and wild-type tumors. RESULTS: USP8 variants were detected in 22 adenomas (23.9%) with higher prevalence in women (28.9% vs. 5.3% in men; p < 0.05). No significant difference in hormonal levels and tumoral features in relation to USP8 status was observed. Interestingly, USP8-variant carriers were more likely to achieve surgical remission than wild-type adenomas (100% vs. 75.7%; p = 0.01). Conversely, recurrence of CD occurred in 23% of USP8-mutated patients and in 13% of patients with wild-type adenoma. The recurrence-free survival did not differ significantly between the two groups (p = 0.42). CONCLUSIONS: ACTH-secreting pituitary adenomas carrying somatic USP8 mutations are associated with a greater likelihood of surgical remission in patients operated by a single neurosurgeon. Recurrence rates are not related with USP8-variant status.
PURPOSE: somatic mutations in the ubiquitin-specific protease 8 (USP8) gene have recently been described in patients with Cushing's disease (CD). The aim of the study is to verify whether USP8 mutation may predict early and late outcome of pituitary surgery in patients with CD operated at a single institution. METHODS: We performed a retrospective genetic analysis of 92 adrenocorticotropic hormone (ACTH)-secreting pituitary adenomas. Specimens were screened for USP8 hotspot mutations in the exon 14 with Sanger sequencing. Hormonal and surgical data were compared between USP8 variant carriers and wild-type tumors. RESULTS:USP8 variants were detected in 22 adenomas (23.9%) with higher prevalence in women (28.9% vs. 5.3% in men; p < 0.05). No significant difference in hormonal levels and tumoral features in relation to USP8 status was observed. Interestingly, USP8-variant carriers were more likely to achieve surgical remission than wild-type adenomas (100% vs. 75.7%; p = 0.01). Conversely, recurrence of CD occurred in 23% of USP8-mutated patients and in 13% of patients with wild-type adenoma. The recurrence-free survival did not differ significantly between the two groups (p = 0.42). CONCLUSIONS:ACTH-secreting pituitary adenomas carrying somatic USP8 mutations are associated with a greater likelihood of surgical remission in patients operated by a single neurosurgeon. Recurrence rates are not related with USP8-variant status.
Entities:
Keywords:
Adrenocorticotropin; Cortisol; Pituitary neoplasms; Pituitary surgery
Authors: Bernd Markus Hofmann; Michal Hlavac; Ramon Martinez; Michael Buchfelder; Otto Albrecht Müller; Rudolf Fahlbusch Journal: J Neurosurg Date: 2008-01 Impact factor: 5.115
Authors: Luis G Perez-Rivas; Marily Theodoropoulou; Francesco Ferraù; Clara Nusser; Kohei Kawaguchi; Constantine A Stratakis; Fabio Rueda Faucz; Luiz E Wildemberg; Guillaume Assié; Rudi Beschorner; Christina Dimopoulou; Michael Buchfelder; Vera Popovic; Christina M Berr; Miklós Tóth; Arif Ibrahim Ardisasmita; Jürgen Honegger; Jerôme Bertherat; Monica R Gadelha; Felix Beuschlein; Günter Stalla; Masayuki Komada; Márta Korbonits; Martin Reincke Journal: J Clin Endocrinol Metab Date: 2015-05-05 Impact factor: 5.958
Authors: M Losa; P Mortini; S Dylgjeri; R Barzaghi; A Franzin; C Mandelli; M Giovanelli Journal: Clin Endocrinol (Oxf) Date: 2001-07 Impact factor: 3.478
Authors: Lynnette K Nieman; Beverly M K Biller; James W Findling; M Hassan Murad; John Newell-Price; Martin O Savage; Antoine Tabarin Journal: J Clin Endocrinol Metab Date: 2015-07-29 Impact factor: 5.958
Authors: William F Chandler; Ariel L Barkan; Todd Hollon; Alla Sakharova; Jayson Sack; Barunashish Brahma; David E Schteingart Journal: Neurosurgery Date: 2016-02 Impact factor: 4.654
Authors: Maria Francesca Cassarino; Alberto G Ambrogio; Andrea Cassarino; Maria Rosa Terreni; Davide Gentilini; Antonella Sesta; Francesco Cavagnini; Marco Losa; Francesca Pecori Giraldi Journal: J Neuroendocrinol Date: 2018-08-07 Impact factor: 3.627
Authors: Antonella Sesta; Maria Francesca Cassarino; Mariarosa Terreni; Alberto G Ambrogio; Laura Libera; Donatella Bardelli; Giovanni Lasio; Marco Losa; Francesca Pecori Giraldi Journal: Neuroendocrinology Date: 2019-10-16 Impact factor: 4.914
Authors: Michal Cohen; Rebecca Persky; Rachel Stegemann; Laura C Hernández-Ramírez; Deena Zeltser; Maya B Lodish; Anlu Chen; Margaret F Keil; Christina Tatsi; Fabio R Faucz; David A Buchner; Constantine A Stratakis; Dov Tiosano Journal: J Clin Endocrinol Metab Date: 2019-10-01 Impact factor: 5.958
Authors: Ananth P Abraham; Rekha Pai; Daniel L Beno; Geeta Chacko; Hesarghatta Shyamasunder Asha; Simon Rajaratnam; Nitin Kapoor; Nihal Thomas; Ari G Chacko Journal: Endocrine Date: 2021-10-18 Impact factor: 3.633
Authors: Pietro Locantore; Rosa Maria Paragliola; Gianluca Cera; Roberto Novizio; Ettore Maggio; Vittoria Ramunno; Andrea Corsello; Salvatore Maria Corsello Journal: Int J Mol Sci Date: 2022-06-19 Impact factor: 6.208